Specialized Information Processing Deficits and Distinct Metabolomic Profiles Following TM-Domain Disruption of Nrg1
暂无分享,去创建一个
J. Waddington | B. Pickard | R. Harvey | D. Lai | L. MacIntyre | D. Watson | P. Moran | C. O’Tuathaigh | N. Mathur | M. O'Callaghan
[1] I. McGregor,et al. Endocannabinoid dysregulation in cognitive and stress-related brain regions in the Nrg1 mouse model of schizophrenia , 2017, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[2] C. Buechler,et al. Ceramide and polyunsaturated phospholipids are strongly reduced in human hepatocellular carcinoma. , 2016, Biochimica et biophysica acta.
[3] D. Volk,et al. Altered expression of developmental regulators of parvalbumin and somatostatin neurons in the prefrontal cortex in schizophrenia , 2016, Schizophrenia Research.
[4] R. Gruetter,et al. Genetic Polymorphism Associated Prefrontal Glutathione and Its Coupling With Brain Glutamate and Peripheral Redox Status in Early Psychosis. , 2016, Schizophrenia bulletin.
[5] Yiyun Huang,et al. Reduced Brain Cannabinoid Receptor Availability in Schizophrenia , 2016, Biological Psychiatry.
[6] E. Hoxha,et al. Genetic deletion of fibroblast growth factor 14 recapitulates phenotypic alterations underlying cognitive impairment associated with schizophrenia , 2016, Translational psychiatry.
[7] H. Nawa,et al. Perinatal Exposure to Neuregulin-1 Results in Disinhibition of Adult Midbrain Dopaminergic Neurons: Implication in Schizophrenia Modeling , 2016, Scientific Reports.
[8] J. Waddington,et al. Closing the translational gap between mutant mouse models and the clinical reality of psychotic illness , 2015, Neuroscience & Biobehavioral Reviews.
[9] C. Chiapponi,et al. Brain structure, cognition and negative symptoms in schizophrenia are associated with serum levels of polysialic acid-modified NCAM , 2015, Translational Psychiatry.
[10] S. Matsuoka,et al. Protective effects of polysialic acid on proteolytic cleavage of FGF2 and proBDNF/BDNF. , 2015, Glycobiology.
[11] H. Kaya,et al. Metabolic syndrome in drug-naïve and drug-free patients with schizophrenia and in their siblings , 2015, Schizophrenia Research.
[12] D. Pinault,et al. Neuregulin 1 Expression and Electrophysiological Abnormalities in the Neuregulin 1 Transmembrane Domain Heterozygous Mutant Mouse , 2015, PloS one.
[13] D. Henderson,et al. Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses. , 2015, The lancet. Psychiatry.
[14] Xu-Feng Huang,et al. Differential effects of short- and long-term antipsychotic treatment on the expression of neuregulin-1 and ErbB4 receptors in the rat brain , 2015, Psychiatry Research.
[15] D Lindberg,et al. Purinergic signaling and energy homeostasis in psychiatric disorders. , 2015, Current molecular medicine.
[16] Julie A. Wood,et al. Dysfunctional plasmalogen dynamics in the plasma and platelets of patients with schizophrenia , 2015, Schizophrenia Research.
[17] B. Pickard,et al. Schizophrenia biomarkers: Translating the descriptive into the diagnostic , 2015, Journal of psychopharmacology.
[18] M. Bennett,et al. Partial genetic deletion of neuregulin 1 modulates the effects of stress on sensorimotor gating, dendritic morphology, and HPA axis activity in adolescent mice. , 2014, Schizophrenia bulletin.
[19] C. Turck,et al. Lipidomics reveals dysfunctional glycosynapses in schizophrenia and the G72/G30 transgenic mouse , 2014, Schizophrenia Research.
[20] J. Waddington,et al. Phenotypic effects of maternal immune activation and early postnatal milieu in mice mutant for the schizophrenia risk gene neuregulin-1 , 2014, Neuroscience.
[21] W. Lai,et al. Distinct phenotypes of new transmembrane-domain neuregulin 1 mutant mice and the rescue effects of valproate on the observed schizophrenia-related cognitive deficits , 2014, Front. Behav. Neurosci..
[22] Rita Gerardy-Schahn,et al. Sialic acids in the brain: gangliosides and polysialic acid in nervous system development, stability, disease, and regeneration. , 2014, Physiological reviews.
[23] R. Landgraf,et al. Environmental manipulations generate bidirectional shifts in both behavior and gene regulation in a crossbred mouse model of extremes in trait anxiety , 2014, Front. Behav. Neurosci..
[24] S. Hyman. Time for New Schizophrenia Rx , 2014, Science.
[25] N. Swerdlow,et al. Forebrain gene expression predicts deficits in sensorimotor gating after isolation rearing in male rats , 2013, Behavioural Brain Research.
[26] J. Krauss,et al. Hypomethylation of neuregulin in rats selectively bred for reduced sensorimotor gating , 2013, Schizophrenia Research.
[27] M. Keshavan,et al. Associations between purine metabolites and monoamine neurotransmitters in first-episode psychosis , 2013, Front. Cell. Neurosci..
[28] I. McGregor,et al. Novel molecular changes induced by Nrg1 hypomorphism and Nrg1-cannabinoid interaction in adolescence: a hippocampal proteomic study in mice , 2013, Front. Cell. Neurosci..
[29] H. Nawa,et al. ErbB1-4-dependent EGF/neuregulin signals and their cross talk in the central nervous system: pathological implications in schizophrenia and Parkinson's disease , 2013, Front. Cell. Neurosci..
[30] W. Drevets,et al. Cerebrospinal Fluid Metabolome in Mood Disorders-Remission State has a Unique Metabolic Profile , 2012, Scientific Reports.
[31] Matcheri S. Keshavan,et al. Associations between Purine Metabolites and Clinical Symptoms in Schizophrenia , 2012, PloS one.
[32] D. Rujescu,et al. Schizophrenia shows a unique metabolomics signature in plasma , 2012, Translational Psychiatry.
[33] J. Waddington,et al. Phenotypic effects of repeated psychosocial stress during adolescence in mice mutant for the schizophrenia risk gene neuregulin-1: A putative model of gene×environment interaction , 2012, Brain, Behavior, and Immunity.
[34] K. Newell,et al. Perinatal phencyclidine treatment alters neuregulin 1/erbB4 expression and activation in later life , 2012, European Neuropsychopharmacology.
[35] D. Blackwood,et al. Transcriptional regulation of neurodevelopmental and metabolic pathways by NPAS3 , 2012, Molecular Psychiatry.
[36] C. Sato,et al. Novel Regulation of Fibroblast Growth Factor 2 (FGF2)-mediated Cell Growth by Polysialic Acid* , 2011, The Journal of Biological Chemistry.
[37] R. Chesworth,et al. Do transmembrane domain neuregulin 1 mutant mice exhibit a reliable sensorimotor gating deficit? , 2011, Behavioural Brain Research.
[38] C. McBain,et al. Conserved Interneuron-Specific ErbB4 Expression in Frontal Cortex of Rodents, Monkeys, and Humans: Implications for Schizophrenia , 2011, Biological Psychiatry.
[39] Xu-Feng Huang,et al. Antipsychotic treatment and neuregulin 1–ErbB4 signalling in schizophrenia , 2011, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[40] A. Kakita,et al. Transient exposure of neonatal mice to neuregulin-1 results in hyperdopaminergic states in adulthood: implication in neurodevelopmental hypothesis for schizophrenia , 2011, Molecular Psychiatry.
[41] A. Ennaceur. One-trial object recognition in rats and mice: Methodological and theoretical issues , 2010, Behavioural Brain Research.
[42] M. Ozaki,et al. Phenotypic Characterization of Transgenic Mice Overexpressing Neuregulin-1 , 2010, PloS one.
[43] Tilo Kircher,et al. The effect of Neuregulin 1 on neural correlates of episodic memory encoding and retrieval , 2010, NeuroImage.
[44] T. Karl,et al. Cognition in transmembrane domain neuregulin 1 mutant mice , 2010, Neuroscience.
[45] J. Waddington,et al. Advancing a functional genomics for schizophrenia: Psychopathological and cognitive phenotypes in mutants with gene disruption , 2010, Brain Research Bulletin.
[46] Richard S. Ehrlichman,et al. Mouse behavioral endophenotypes for schizophrenia , 2010, Brain Research Bulletin.
[47] A. Buonanno,et al. The neuregulin signaling pathway and schizophrenia: From genes to synapses and neural circuits , 2010, Brain Research Bulletin.
[48] J. Lieberman,et al. Signaling pathways in schizophrenia: emerging targets and therapeutic strategies. , 2010, Trends in pharmacological sciences.
[49] G. Rouleau,et al. Association of NPAS3 exonic variation with schizophrenia , 2010, Schizophrenia Research.
[50] R. Chesworth,et al. A follow-up study: acute behavioural effects of Δ9-THC in female heterozygous Neuregulin 1 transmembrane domain mutant mice , 2010, Psychopharmacology.
[51] H. Nawa,et al. Measurement and comparison of serum neuregulin 1 immunoreactivity in control subjects and patients with schizophrenia: an influence of its genetic polymorphism , 2010, Journal of Neural Transmission.
[52] J. Gogos,et al. Cognition in mouse models of schizophrenia susceptibility genes. , 2010, Schizophrenia bulletin.
[53] M. Rietschel,et al. Gene expression of neuregulin-1 isoforms in different brain regions of elderly schizophrenia patients , 2010, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.
[54] R. Harvey,et al. Schizophrenia‐related endophenotypes in heterozygous neuregulin‐1 ‘knockout’ mice , 2010, The European journal of neuroscience.
[55] Xin-Hong Zhu,et al. Neuregulin 1 regulates pyramidal neuron activity via ErbB4 in parvalbumin-positive interneurons , 2009, Proceedings of the National Academy of Sciences.
[56] I. Weiner,et al. Using the pharmacology of latent inhibition to model domains of pathology in schizophrenia and their treatment , 2009, Behavioural Brain Research.
[57] M. van den Buuse,et al. Neuregulin 1 hypomorphic mutant mice: enhanced baseline locomotor activity but normal psychotropic drug-induced hyperlocomotion and prepulse inhibition regulation. , 2009, The international journal of neuropsychopharmacology.
[58] K L Evans,et al. Interacting haplotypes at the NPAS3 locus alter risk of schizophrenia and bipolar disorder , 2009, Molecular Psychiatry.
[59] Q. Xing,et al. A two-method meta-analysis of Neuregulin 1(NRG1) association and heterogeneity in schizophrenia , 2009, Schizophrenia Research.
[60] J. Waddington,et al. Enhanced latent inhibition in dopamine receptor-deficient mice is sex-specific for the D1 but not D2 receptor subtype: implications for antipsychotic drug action. , 2009, The international journal of neuropsychopharmacology.
[61] F. Dickerson,et al. A double-blind trial of adjunctive allopurinol for schizophrenia , 2009, Schizophrenia Research.
[62] Claudia S. Barros,et al. Impaired maturation of dendritic spines without disorganization of cortical cell layers in mice lacking NRG1/ErbB signaling in the central nervous system , 2009, Proceedings of the National Academy of Sciences.
[63] P. McKenna,et al. High throughput lipidomic profiling of schizophrenia and bipolar disorder brain tissue reveals alterations of free fatty acids, phosphatidylcholines, and ceramides. , 2008, Journal of proteome research.
[64] Jing-ping Zhao,et al. Explorative study on the expression of neuregulin-1 gene in peripheral blood of schizophrenia , 2008, Neuroscience Letters.
[65] T. Si,et al. Chronic antipsychotic drug administration alters the expression of neuregulin 1beta, ErbB2, ErbB3, and ErbB4 in the rat prefrontal cortex and hippocampus. , 2008, The international journal of neuropsychopharmacology.
[66] L. Mei,et al. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia , 2008, Nature Reviews Neuroscience.
[67] Laura L. Vernon,et al. Cognitive correlates of schizophrenia signs and symptoms: III. Hallucinations and delusions , 2008, Psychiatry Research.
[68] M. Webster,et al. Elevated neuregulin-1 and ErbB4 protein in the prefrontal cortex of schizophrenic patients , 2008, Schizophrenia Research.
[69] L. Hong,et al. Evidence of Missense Mutations on the Neuregulin 1 Gene Affecting Function of Prepulse Inhibition , 2008, Biological Psychiatry.
[70] M. Munafo,et al. Neuregulin 1 genotype and schizophrenia. , 2007, Schizophrenia bulletin.
[71] P. Schofield,et al. Altered motor activity, exploration and anxiety in heterozygous neuregulin 1 mutant mice: implications for understanding schizophrenia , 2007, Genes, brain, and behavior.
[72] J. Waddington,et al. Phenotypic characterization of spatial cognition and social behavior in mice with ‘knockout’ of the schizophrenia risk gene neuregulin 1 , 2007, Neuroscience.
[73] Roberto Malinow,et al. The Neuregulin-1 Receptor ErbB4 Controls Glutamatergic Synapse Maturation and Plasticity , 2007, Neuron.
[74] Kari Stefansson,et al. Neuregulin1 (NRG1) Signaling through Fyn Modulates NMDA Receptor Phosphorylation: Differential Synaptic Function in NRG1+/− Knock-Outs Compared with Wild-Type Mice , 2007, The Journal of Neuroscience.
[75] K. Krishnan,et al. Metabolomic mapping of atypical antipsychotic effects in schizophrenia , 2007, Molecular Psychiatry.
[76] P. Schofield,et al. Heterozygous neuregulin 1 mice are more sensitive to the behavioural effects of Δ9-tetrahydrocannabinol , 2007, Psychopharmacology.
[77] Daniel R Weinberger,et al. expression in the brain , 2006 .
[78] J. P. Huston,et al. The case for episodic memory in animals , 2006, Neuroscience & Biobehavioral Reviews.
[79] M. Reveley,et al. Measuring memory impairment in community-based patients with schizophrenia , 2006, British Journal of Psychiatry.
[80] Paul J. Harrison,et al. Neuregulin 1 and Schizophrenia: Genetics, Gene Expression, and Neurobiology , 2006, Biological Psychiatry.
[81] Karin E. Borgmann-Winter,et al. Altered neuregulin 1–erbB4 signaling contributes to NMDA> receptor hypofunction in schizophrenia , 2006, Nature Medicine.
[82] Paul J. Harrison,et al. Neuregulin 1 transcripts are differentially expressed in schizophrenia and regulated by 5' SNPs associated with the disease. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[83] Joseph P. Huston,et al. Wistar rats show episodic-like memory for unique experiences , 2006, Neurobiology of Learning and Memory.
[84] F. Lee,et al. Neurotrophin signalling in health and disease. , 2006, Clinical science.
[85] R. Harrington,et al. Identification of Disease Markers in Human Cerebrospinal Fluid Using Lipidomic and Proteomic Methods , 2005, Disease markers.
[86] Joseph P. Huston,et al. Integrated memory for objects, places, and temporal order: Evidence for episodic-like memory in mice , 2005, Neurobiology of Learning and Memory.
[87] Douglas W. Barrett,et al. Neuregulin-1 immunoglobulin-like domain mutant mice: clozapine sensitivity and impaired latent inhibition , 2005, Neuroreport.
[88] Michael F. Green,et al. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS , 2004, Schizophrenia Research.
[89] Tobias M. Fischer,et al. Short- and Long-Range Attraction of Cortical GABAergic Interneurons by Neuregulin-1 , 2004, Neuron.
[90] C. Byrne,et al. Schizophrenia, the metabolic syndrome and diabetes , 2004, Diabetic medicine : a journal of the British Diabetic Association.
[91] R Hashimoto,et al. Expression analysis of neuregulin-1 in the dorsolateral prefrontal cortex in schizophrenia , 2004, Molecular Psychiatry.
[92] H. Stefánsson,et al. Neuregulin 1 and susceptibility to schizophrenia. , 2002, American journal of human genetics.
[93] Ronan E. O'Carroll,et al. Cognitive impairment in schizophrenia , 2000 .
[94] Jeffrey K. Yao,et al. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients , 2000, Schizophrenia Research.
[95] D. Weinberger,et al. Cognitive deficits and the neurobiology of schizophrenia , 1995, Current Opinion in Neurobiology.
[96] R. Quirion,et al. Decreased expression of the embryonic form of the neural cell adhesion molecule in schizophrenic brains. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[97] J. Waddington,et al. Dopaminergic function in relation to genes associated with risk for schizophrenia: translational mutant mouse models. , 2014, Progress in brain research.
[98] J. Waddington,et al. Mutant mouse models in evaluating novel approaches to antipsychotic treatment. , 2012, Handbook of experimental pharmacology.
[99] Sarah Tosato,et al. Association between the neuregulin 1 gene and schizophrenia: a systematic review. , 2005, Schizophrenia bulletin.